# Roche to build $283M biopharmaceutical facility in Shanghai

Roche announced plans to invest 2.04 billion yuan ($283 million) to build a new biopharmaceutical manufacturing facility in Shanghai's Pudong New Area. The facility will produce Vabysmo, a bispecific antibody for eye diseases, and is expected to be completed in 2029 and begin operations in 2031.

- Type: New facility
- Announced: 2025-05-09
- Where: Zhangjiang High-tech Park, Pudong, Shanghai, China
- Value: $283.0M (2.04B CNY)
- Starts operating: 2031
- Status: announced
- Products: Vabysmo (bispecific antibody for eye diseases)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Roche Holdings Inc](https://endata.com/companies/16415.md)

## Sources

- [global.chinadaily.com.cn](http://global.chinadaily.com.cn/a/202505/09/WS681d5be0a310a04af22be4b3.html), 2025-05-09: "Our commitment to China remains unchanged, not only today but also for the years to come, and this new site marks a significant milestone in our journey."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.